Itraconazole capsules should be taken with a full meal to ensure maximal
Itraconazole capsules are a different preparation than itraconazole oral
solution and should not be used interchangeably.
Treatment of Blastomycosis and Histoplasmosis
The recommended dose is 200 mg once daily (2 capsules). If there is no obvious
improvement or there is evidence of progressive fungal disease, the dose should
be increased in 100 mg increments to a maximum of 400 mg daily. Doses above 200
mg/day should be given in two divided doses.
Treatment of Aspergillosis
A daily dose of 200 mg to 400 mg is recommended.
Treatment in Life-Threatening Situations
In life-threatening situations, a loading dose should be used whether given as
oral capsules or intravenously.
IV Injection: the recommended intravenous dose
is 200 mg b.i.d. for four consecutive doses, followed by 200 mg once daily
thereafter. Each intravenous dose should be infused over 1 hour. The safety and
efficacy of itraconazole injection administered for greater than 14 days is not
known. See complete prescribing information for itraconazole injection.
Capsules: although clinical studies did not provide for a loading dose, it is
recommended, based on pharmacokinetic data, that a loading dose of 200 mg (2
capsules) three times daily (600 mg/day) be given for the first 3 days of
Treatment should be continued for a minimum of three months and until clinical
parameters and laboratory tests indicate that the active fungal infection has
subsided. An inadequate period of treatment may lead to recurrence of active
Itraconazole capsules and itraconazole oral solution should not be used
interchangeably. Only the oral solution has been demonstrated effective for oral
and/or esophageal candidiasis.
Treatment of Onychomycosis
Toenails with or without fingernail involvement: The recommended dose is 200 mg
(2 capsules) once daily for 12 consecutive weeks.
Treatment of Onychomycosis
Fingernails only: The recommended dosing regimen is 2 treatment pulses, each
consisting of 200 mg (2 capsules) b.i.d. (400 mg/day) for 1 week. The pulses are
separated by a 3-week period without itraconazole.
Use in Patients with Renal Impairment
Limited data are available on the use of oral itraconazole in patients
with renal impairment. Caution should be exercised when this drug is
administered in this patient population
National Institutes of Health, U.S. National Library of Medicine,
DailyMed Database. Provides access to the latest drug monographs submitted to the
Food and Drug Administration (FDA). Please review the latest applicable package insert for
additional information and possible updates. A local search
option of this data can be found here.
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical
judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.PLEASE READ THE DISCLAIMER
BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU
AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read